PRAX
Praxis Precision Medicines, Inc. Common StockstockNASDAQ
praxis precision medicines, inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. its lead product candidates include prax-114, an extrasynaptic-preferring gabaa receptor positive allosteric modulator that is in phase iia clinical trial for the treatment of major depressive disorder and perimenopausal depression; and prax-944, a selective small molecule inhibitor of t-type calcium channels, which is in phase iia clinical trial for the treatment of essential tremor. the company is also developing prax-562, a persistent sodium current blocker that is in phase i clinical trial to treat severe pediatric epilepsy and adult cephalgia; prax-222, an antisense oligonucleotide for patients with gain-of-function (gof) scn2a epilepsy; and kcnt1 program for the treatment of kcnt1 gof epilepsy. it has a cooperation and license agreement with rogcon inc.; a license agreement purdue neuroscience company; and a res
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 346.21 | 2026-11-11 | -11.94% | 1.688 |
| 1M | 260.17 | 2026-10-19 | +17.18% | 2.871 |
| 3M | 369.84 | 2026-08-18 | -17.57% | 2.388 |
| 6M | 320.53 | 2026-05-18 | -4.89% | 1.569 |
| 1Y | 184.13 | 2025-11-18 | +65.57% | 1.624 |
| 2Y | 71.51 | 2024-11-18 | +326.32% | — |
| 5Y | 281.70 | 2021-11-18 | +8.22% | 1.035 |
Praxis Precision Medicines, Inc. Common Stock (NASDAQ:PRAX) stock price today is $304.86, and today's volume is 425,752. PRAX is down 0.066% today. The 30 day average volume is 533,518. PRAX market cap is $8.52B with 27.95M shares outstanding.